Tag: Oxford

Poster-Methods of Care

Remote Monitoring in MS – Initial Experience with Medical Device Icompanion

Background: In the last decade, many electronic health (eHealth) technologies have found their way to the field of multiple sclerosis (MS)....

Read More

Poster-Imaging

Relationship of Functional Outcomes and Routinely Performed MRI Studies in Persons with Multiple Sclerosis: An Insight into the Frontal Lobe Structural Alterations

Background: Functional outcomes in multiple sclerosis (MS) have been thoroughly investigated over the last few decades. The Frontal lobe...

Read More

Poster-Imaging

Trajectories of the Frontal Lobe Structural Changes in Relation to Retrospective and Prospective Memory in Persons with Multiple Sclerosis

Background: Sophisticated cognitive and intellectual abilities are known to be attributed to the highly convoluted gyrencephalic brain in...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...

Read More

Poster-Disease-modifying Therapy

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent

Background: In PREVENT, eculizumab was associated with a significant reduction in relapse risk versus placebo and was well tolerated. In...

Read More

Poster-Disease-modifying Therapy

Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder

Background: Neuromyelitis optica spectrum disorder (NMOSD) relapses can cause significant and irreversible neurologic disability. In...

Read More

Platform-Disease Modifying Therapies

Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design

Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...

Read More

Platform-Neuroimaging

International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS

Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...

Read More